Company Description
vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases.
The company’s lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of postprandial hyperglycemia in cystic fibrosis related diabetes patients, as well as in Phase II trial for the treatment of type 2 diabetes.
It is also developing HPP737, an orally administered non- central nervous system penetrant PDE4 inhibitor that has completed Phase 1 trials for the treatment of inflammatory diseases.
In addition, the company’s other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2–related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress.
It has a license agreement Newsoara Biopharma Co., Ltd. o develop and commercialize phosphodiesterase type 4 inhibitors program, including the compound HPP737.
The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Group LLC.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jul 30, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 23 |
| CEO | Paul Sekhri |
Contact Details
Address: 3980 Premier Drive, Suite 310 High Point, North Carolina 27265 United States | |
| Phone | 336 841 0300 |
| Website | vtvtherapeutics.com |
Stock Details
| Ticker Symbol | VTVT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001641489 |
| CUSIP Number | 918385105 |
| ISIN Number | US9183852048 |
| Employer ID | 47-3916571 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Paul J. Sekhri M.Sc. | Chief Executive Officer, President and Chairman of the Board |
| Dr. Michael Steven Tung M.B.A., M.D. | Executive Vice President and Chief Financial Officer |
| Barry K. Brown | Chief Accounting Officer |
| Dr. Carmen Valcarce Ph.D. | Chief Scientific Officer and Executive Vice President |
| Elizabeth M. Keiley | Executive Vice President and General Counsel |
| Richard S. Nelson | Executive Vice President of Corporate Development and Director |
| Dr. Thomas Strack M.D., Ph.D. | Chief Medical Officer |
| Martin Lafontaine | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 12, 2025 | 10-Q | Quarterly Report |
| Aug 12, 2025 | 8-K | Current Report |
| Jun 12, 2025 | 8-K | Current Report |
| May 19, 2025 | 8-K | Current Report |
| May 16, 2025 | 8-K | Current Report |
| May 15, 2025 | 8-K | Current Report |
| May 15, 2025 | 10-Q | Quarterly Report |
| May 1, 2025 | 144 | Filing |
| Apr 29, 2025 | 144 | Filing |
| Apr 25, 2025 | DEF 14A | Other definitive proxy statements |